Education And Debate Cochrane at crossroads over drug company sponsorship BMJ 2003; 327 doi: https://doi.org/10.1136/bmj.327.7420.924 (Published 16 October 2003) Cite this as: BMJ 2003;327:924 Article Related content Metrics Responses Peer review Related articles News Roundup [abridged Versions Appear In The Paper Journal] Cochrane proposes further limits on commercial funding Published: 12 February 2004; BMJ 328 doi:10.1136/bmj.328.7436.366 See more Hearing loss in adults, assessment and management: summary of NICE guidance BMJ June 22, 2018, 361 k2219; DOI: https://doi.org/10.1136/bmj.k2219 Sixty seconds on . . . parkrun BMJ June 22, 2018, 361 k2767; DOI: https://doi.org/10.1136/bmj.k2767 Brexit—an impartial view? BMJ June 22, 2018, 361 k2743; DOI: https://doi.org/10.1136/bmj.k2743 Head of GP partnership review dismisses Darzi’s call for salaried profession BMJ June 22, 2018, 361 k2758; DOI: https://doi.org/10.1136/bmj.k2758 What readers thought about The BMJ’s call to legalise drugs BMJ June 22, 2018, 361 k2664; DOI: https://doi.org/10.1136/bmj.k2664 Cited by... New Cochrane policy tightens limits on industry fundingFulltext PDF
